- Qiagen NV QGEN has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function.
- QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiagen portfolio for CRISPR applications.
- The solutions allow researchers to analyze edited genetic material with speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
- The new products add to the range of Qiagen products that could also be used for CRISPR research, such as the QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits.
- Price Action: QGEN shares closed at $47.26 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
